Bachem enlarges its footprint in Asia with new Japanese subsidiary
News | Bachem AG
OCTOBER 03, 2018
Bubendorf, Switzerland: –Peptide technology specialist Bachem AG has announced the establishment of a new entity in Tokyo, to trade as Bachem Japan K.K.
This new Bachem Japanese subsidiary will give Bachem greater local presence in Asia that will strengthen its customer and project support and drive further growth in a rapidly growing market.
Bachem Japan K.K. will assume sales responsibility for Bachem’s Active Pharmaceutical Ingredients (APIs) business in Japan and in other Asian countries such as e.g. South Korea, China and Taiwan.
Third global pillar
Dr. Anne-Kathrin Stoller, Chief Marketing Officer at Bachem Holding AG, commented: “This is an exciting step for Bachem.”
“The Asian market and Japan in particular have become ever more important for Bachem,” said Dr. Stoller.
Pioneering Partner for Peptides
“Therefore, we decided to establish a third regional pillar for our global representation to join Europe and North America,” she explained.
“Thus, we will be able to serve our customers even more effectively as a Pioneering Partner for Peptides and to expand our business in Asia, working together with our existing partners and beyond,” said Dr. Stoller.
The Bachem Group is a listed, technology-based company focused on peptide chemistry. Bachem is the world’s only full service provider of peptides and provides a full range of other services to the pharma and biotech industries.
Under its banner Pioneering Partner for Peptides, Bachem specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients (APIs). A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete its service portfolio.
Headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach with more experience and know-how than any other company in the industry. Bachem shows total commitment to quality, innovation and partnership, prioritizing continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has six production sites in the U.S. and in Europe along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, new chemical entities (NCEs) and finished dosage forms at preclinical, clinical and production scales.
Dr. Martina Diekmann, Vice-President, Global Marketing, Bachem Group
Tel: +41 799 459 107